Drug Profile


Alternative Names: Elisidepsin trifluoroacetate; Irvalec; PM 02734; PM-2734

Latest Information Update: 12 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaMar
  • Class Antineoplastics; Depsipeptides
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 09 Apr 2012 Suspended - Phase-I for Solid tumours (combination therapy) in Spain (IV)
  • 09 Apr 2012 Suspended - Phase-I for Solid tumours in USA (IV)
  • 09 Apr 2012 Suspended - Phase-II for Gastric cancer in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top